| This week's sponsor is Premier Research. | |  | Rare Oncology Drug Advances. What's In It For You?
Take a look at how new drug development processes and regulatory pathways are helping speed development of novel therapies, including adaptive design strategies, endpoint selection, and effectively using biomarkers. Download our latest white paper now.
Premier Research. It's what we do. Best. |
Featured Story | | | Friday, June 16, 2017 Idorsia has spun out of Actelion after Johnson & Johnson wrapped up its $30 billion takeover of the Swiss biotech. The new company starts life with $1 billion in cash, multiple clinical-phase drugs and a deal with J&J, strengths that prompted traders to drive up its share price by 30% in its first hours on the Swiss stock exchange. |
|
|
| This week's sponsor is Medpace. | |  | |
Top Stories Friday, June 16, 2017 A new funding round for Checkmate Pharma will fund additional trials of immuno-oncology drug CMP-001, currently paired with Merck's Keytruda in a phase 1b melanoma trial. Friday, June 16, 2017 Bavarian Nordic has again delayed the release of data from a phase 3 trial of Prostvac. Top-line data on the Bristol-Myers Squibb-partnered prostate cancer vaccine are now due to drop in the fourth quarter, with the delayed third interim analysis penciled in for September. Monday, June 12, 2017 “Patient centricity must be grounded in an engagement approach for the patients … ” Jonathan Zung, PhD, Covance. How do clinical research organizations (CROs) respond and support this increasing focus on patient-centric practices? Friday, June 16, 2017 Six years after Pfizer's landmark REMOTE trial, Parexel and Sanofi are teaming up in a pilot study to revisit the idea of using wearables in clinical trials. Friday, June 16, 2017 Merck KGaA has teamed up with J. Craig Venter’s Human Longevity, Inc. to identify biomarkers that suggest melanoma patients will respond to pimasertib. The agreement follows a two-year lull in development of the MEK1/2 inhibitor precipitated by mixed data from a phase 2 trial. Friday, June 16, 2017 Bristol-Myers Squibb, which is shifting its focus toward biologics manufacturing, will unload an API plant in Ireland to a South Korean company that has aspirations of becoming a big deal in contract manufacturing. Thursday, June 15, 2017 In this week's EuroBiotech Report, Medicxi unveils $300 million fund, Sanofi partner posts data, the U.K. election rocks biotech and more. Friday, June 16, 2017 Drug regulators from Europe, the U.S. and Japan have come together to boost antibiotic development, South Korea's SK Biotek has purchased an API plant from Bristol-Myers Squibb, and Japan's JSR has acquired Swiss cell line developer Selexis. Friday, June 16, 2017 Biogen lost its longtime CFO Paul Clancy to Alexion but poached Jean-Paul Kress from Sanofi Genzyme to head its operations outside the U.S., and life sciences VC Flagship brought on J.P. Morgan vet Stephen Berenson as an executive partner. Plus more hirings, firings and retirings throughout the industry. | This week's sponsor is Cmed. | |  | |
| | | Xencor posted a snapshot of data from its ongoing midstage test of XmAb 5871 in patients with active IgG4-related disease, showing that 93% of patients achieved a response to therapy. Statement Cancer biotech Mersana Therapeutics plans to raise $75 million by offering 5 million shares at a price range of $14 to $16 apiece. Renaissance Capital article PharmaMar said that its latest cancer drug PM1183 (lurbinectedin), its third molecule of marine origin and analogue of marketed medication Yondelis, will go by the name Zepsyre. Release | |
|
Resources Presented by: Veeva Hear three innovative leaders explain how regulatory can “go digital” in their operations by leveraging the data-handling capabilities in their RIM systems. Sponsored By: Envigo Discover the factors that contribute to differential radiation sensitivity between the Rag2 and SCID models. Sponsored by Envigo Performing a sophisticated surgery to create a myocardial infarction model. Join us on June 7th at 11:00 AM EDT. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Sponsored By: HealthCore Gain critical insights into how to design and implement pragmatic trials and generate relevant, high-level real-world evidence. Learn when to conduct PTs, design considerations, ethical regulatory issues — and more. Sponsored By: Veeva Join this global webinar to learn a new approach for demonstrating medical affairs' impact with better metrics - beyond reach and frequency, enabling launch success and better engagement with strategic KOL insights, and increasing your organization's share of voice in the healthcare landscape. Sponsored By: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Sponsored By: DocuSign The patients who rely on your scientific leadership are expecting more. Sponsored By: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. |
|
